OPCH

Option Care Health (OPCH) surged 32.7% following the announcement of its acquisition by CD&R and McKesson for $32.05 per share in cash, representing a 37% premium to the previous closing price. The $5.8 billion enterprise value deal underscores the strategic appeal of OPCH's home and alternate-site infusion care platform. However, with unchanged earnings estimate revisions over the past 30 days, analysts caution that sustained momentum may depend on future estimate trends.

Halper Sadeh LLC, an investor rights law firm, is investigating PTC Inc. and Option Care Health, Inc. for potential violations of federal securities laws and breaches of fiduciary duties relating to their proposed acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits or terms limiting competing offers are present in these transactions.

Zacks identifies Option Care Health (OPCH) as an attractive value stock opportunity, holding a Zacks Rank #2 (Buy) and Value grade of A. The company trades at a P/E ratio of 15.09, below its industry average of 18.05, and demonstrates favorable valuations across multiple metrics including P/B, P/S, and P/CF ratios compared to industry peers.

Zacks highlights two healthcare stocks as strong value investment opportunities: Fresenius SE & Co. (FSNUY) with a Zacks Rank #2 and Value grade A, trading at a P/E of 13.26 below its industry average of 18.36; and Option Care Health (OPCH) also with Rank #2 and Value grade A, trading at a forward P/E of 15.09. Both stocks are presented as undervalued based on multiple valuation metrics including P/S, P/CF, and P/B ratios.

Several stocks surged following major announcements: AMD rose 2.8% on plans to boost chip production in 2027 for AI demand. Constellation Energy jumped 12.3% after Google signed a $4.3 billion nuclear power deal.

Option Care Health soared 32.7% on acquisition news from McKesson and Clayton, Dubilier & Rice. Vistra Corp. gained 10.8% after the Department of Energy committed $4.2 billion for nuclear facility upgrades.

Option Care Health agreed to be acquired by McKesson and private equity firm Clayton, Dubilier & Rice for $32.05 per share, valuing the company at approximately $5.8 billion. The deal represents a 37% premium to Monday's closing price and is expected to close in the first half of 2027. CD&R will hold 51% of the company while McKesson retains 49%, with a framework allowing McKesson to acquire CD&R's stake in the future.

BrightSpring Health Services is leveraging AI and automation across hiring, intake, documentation, and patient care to improve productivity. The company reported 44% year-over-year adjusted EBITDA growth with margin expansion to 5.3%, with further benefits expected in late 2026 and early 2027. Peers Option Care Health and Addus HomeCare are similarly implementing AI-driven initiatives to enhance efficiency and reduce operational complexity.